Lin BioScience, Inc.

銵?鋆蔭?詨

FIRST-IN-CLASS

DRUG TREATMENTS

Lin BioScience is focused on discovering and developing innovative
drug candidate for the treatment of cancer and eye diseases

ORAL DRUG TREATMENT

for MACULAR DEGENERATION

First-in-Class oral therapeutic candidate for Dry Age-related Macular Degeneration and Stargardt Disease

TARGET THERAPY

with BROAD ONCOLOGY APPLICATIONS

Natural small molecular inhibitor for treatment of broad variety of cancers

NEWS

Nov 27 , 2024 Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007 TAIPEI CITY, Taiwan, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Lin BioScience (6696. Taiwan OTC), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting acute leukemia that have significant unmet medical needs, today announced that its lead pipeline, LBS-007, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia. Lin BioScience is currently conducting a phase 1/2 trial in patients with relapsed or resistant acute leukemias in the US, Australia, and Taiwan, and has been granted for orphan drug designation (ODD) for acute myeloid leukemia and acute lymphocytic leukemia by the U.S. FDA.

Jul 09 , 2021 Belite Bio Announces Start of LBS-008 Phase 3 Stargardt Disease Trial Lin BioScience’s subsidiary, Belite Bio, a clinical stage biopharmaceutical drug development company announced the initiation of Phase 3 clinical trial in Stargardt disease for tinlarebant (LBS-008).

Sep 16 , 2020 Lin BioScience raises $30 million in its rights issue to support LBS-008’s phase 3 clinical trial to treat Stargardt disease Lin BioScience today announced that it has successfully completed its $30 million Rights Issue. The new funding will enable Lin BioScience to continue to invest in its subsidiary Belite Bio to pursue the Phase 3 clinical trial of its lead RBP4 antagonist LBS-008 for Stargardt disease.

THERAPEUTIC AREAS